Zobrazeno 1 - 10
of 1 786
pro vyhledávání: '"P. Schöffski"'
Autor:
P. Schöffski, I. Timmermans, D. Hompes, M. Stas, Veerle Boecxstaens, F. Sinnaeve, P. De Leyn, W. Coosemans, D. Van Raemdonck, E. Hauben, R. Sciot, P. Clement, O. Bechter, B. Beuselinck, F. J. S. H. Woei-A-Jin, H. Dumez, P. Nafteux, T. Wessels
Publikováno v:
Sarcoma, Vol 2021 (2021)
Externí odkaz:
https://doaj.org/article/d0edcb49e20845a4bcf298cb8e5512f0
Autor:
P. Schöffski, I. Timmermans, D. Hompes, M. Stas, F. Sinnaeve, P. De Leyn, W. Coosemans, D. Van Raemdonck, E. Hauben, R. Sciot, P. Clement, O. Bechter, B. Beuselinck, F. J. S. H. Woei-A-Jin, H. Dumez, P. Nafteux, T. Wessels
Publikováno v:
Sarcoma, Vol 2020 (2020)
Background. Solitary fibrous tumor (SFT) is a rare variant of soft tissue sarcoma (STS). Materials and Methods. We reviewed SFT patients (pts) treated at our institution between 12/1990 and 09/2017. Results. We identified 94 pts with a median follow-
Externí odkaz:
https://doaj.org/article/c20d4c6835c8495e9e816af9de928526
Autor:
Lore De Cock, Flavia Paternostro, Ulla Vanleeuw, Karo Wyns, Annouschka Laenen, Che-Jui Lee, Raf Sciot, Agnieszka Wozniak, Patrick Schöffski
Publikováno v:
Translational Oncology, Vol 48, Iss , Pp 102057- (2024)
Background: Synovial sarcoma (SynSa) is one of the most common translocation-related soft tissue sarcomas. Patients with metastatic SynSa have limited treatment options and a very poor prognosis. Several novel experimental therapies are currently bei
Externí odkaz:
https://doaj.org/article/1849db8fb1904ffe95310ec132df2b55
Autor:
Tom Vandaele, Jan Van Slambrouck, Patrick Schöffski, Herlinde Dumez, Birgit Weynand, Raf Sciot, Annalisa Barbarossa, An-Lies Provoost, Kristof Van de Voorde, Yves Debaveye, Sofian Bouneb, Philippe Nafteux, Laurens J. Ceulemans
Publikováno v:
World Journal of Surgical Oncology, Vol 22, Iss 1, Pp 1-12 (2024)
Abstract Background Pleural neoplasms are rare and can be subdivided into pleural metastasis and primary pleural neoplasms. Non-mesothelioma primary pleural neoplasms are a diverse group of extremely rare pathologies. Case presentation In this case s
Externí odkaz:
https://doaj.org/article/3b9699ca8efa44beb4a7a5afbe584a46
Autor:
Chia-Chi Lin, Elena Garralda, Patrick Schöffski, David S. Hong, Lillian L. Siu, Miguel Martin, Michela Maur, Rina Hui, Ross A Soo, Joanne Chiu, Tian Zhang, Brigette Ma, Chrisann Kyi, Daniel SW Tan, Philippe A. Cassier, John Sarantopoulos, Andrew Weickhardt, Richard D. Carvajal, Jennifer Spratlin, Taito Esaki, Fréderic Rolland, Wallace Akerley, Barbara Deschler-Baier, Lawrence Rispoli, Tanay S. Samant, Niladri Roy Chowdhury, Daniel Gusenleitner, Eunice L. Kwak, Vasileios Askoxylakis, Filippo De Braud
Publikováno v:
OncoImmunology, Vol 13, Iss 1 (2024)
ABSTRACTIeramilimab, a humanized anti-LAG-3 monoclonal antibody, was well tolerated in combination with the anti-PD-1 antibody spartalizumab in a phase 1 study. This phase 2 study aimed to further investigate the efficacy and safety of combination tr
Externí odkaz:
https://doaj.org/article/fba32163599d40e7abcb0008f2589a1a
Autor:
Alexandra Leary, Paolo A Ascierto, Michele Maio, Georgia Kollia, Jennifer Friedmann, Marina Tschaika, Patrick Schöffski, Jonathan Baden, Neeltje Steeghs, Parul Doshi, Massimo Di Nicola, Jean-Pierre Delord, Iwona Lugowska, Mauricio Burotto, David S P Tan, Anthony Gonçalves, Michael Schenker, Ning Huang, Tudor-Eliade Ciuleanu, Martin Richardet, Lorena Lupinacci, Julieta Grasselli, Jacqueline Vuky, Somasekhar Konduru, Sai Vikram Vemula, Ruta Slepetis, Misena Pacius, Quyen Duong
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 8 (2024)
Background Checkpoint inhibitor therapy has demonstrated overall survival benefit in multiple tumor types. Tumor mutational burden (TMB) is a predictive biomarker for response to immunotherapies. This study evaluated the efficacy of nivolumab+ipilimu
Externí odkaz:
https://doaj.org/article/be397a2c9d104c41b010a59bc9500941
Autor:
Sophie Leboulleux, Ellen Kapiteijn, Saskia Litière, Patrick Schöffski, Yann Godbert, Patrice Rodien, Barbara Jarzab, Domenico Salvatore, Sylvie Zanetta, Jaume Capdevila, Lars Bastholt, Christelle De La Fouchardiere, Yassine Lalami, Stéphane Bardet, Frank Cornélis, Marek Dedecjus, Thera Links, Ward Sents, Martin Schlumberger, D. Laura Locati, Katie Newbold
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
BackgroundNintedanib is a triple-angiokinase inhibitor with potential activity in patients with advanced thyroid cancers, as radioiodine refractory differentiated thyroid cancer (RAIR DTC) and medullary thyroid cancer (MTC).DesignEORTC-1209 (NCT01788
Externí odkaz:
https://doaj.org/article/6cb94876a3044358996b174c5e0cfcd4
Autor:
Rafael Zago Baltazar, Sofie Claerhout, Sara Vander Borght, Lien Spans, Raphael Sciot, Patrick Schöffski, Daphne Hompes, Friedl Sinnaeve, Hazem Wafa, Marleen Renard, Mari FCM van den Hout, Astrid Vernemmen, Louis Libbrecht, An‐Katrien De Roo, Filomena Mazzeo, Cédric van Marcke, Karen Deraedt, Claire Bourgain, Isabelle Vanden Bempt
Publikováno v:
The Journal of Pathology: Clinical Research, Vol 10, Iss 3, Pp n/a-n/a (2024)
Abstract The identification of gene fusions has become an integral part of soft tissue and bone tumour diagnosis. We investigated the added value of targeted RNA‐based sequencing (targeted RNA‐seq, Archer FusionPlex) to our current molecular diag
Externí odkaz:
https://doaj.org/article/a4e531c2073947398417e6e0aa6c457f
Autor:
G. Huygh, Paul M. J. Clement, H. Dumez, P. Schöffski, H. Wildiers, J. Selleslach, J. M. Jimeno, I. De Wever, R. Sciot, L. Duck, A. T. Van Oosterom
Publikováno v:
Sarcoma, Vol 2006 (2006)
Purpose. To evaluate the activity and safety of ecteinascidin (ET-743) in pretreated patients with advanced or metastatic soft tissue and bone sarcoma. Patients or subjects. Eighty-nine patients received ET-743 as a 24-hour continuous infusion at a d
Externí odkaz:
https://doaj.org/article/cabcf7f9911a4f30932b09167f5efa9c
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.